Resmetirom: The First Food and Drug Administration–Approved Medication for Nonalcoholic Steatohepatitis (NASH)

Annals of Pharmacotherapy, Journal Year: 2024, Volume and Issue: unknown

Published: June 17, 2024

Objective: To review the literature leading to Food and Drug Administration (FDA) approval of first medication, resmetirom, for treatment nonalcoholic steatohepatitis (NASH), including pharmacology, pharmacokinetics, clinical studies, dosing, adverse effects. Relevant data will be used discuss how resmetirom impacts practice. Data sources: A search was conducted using MEDLINE from database inception May 12, 2024. Keywords included non-alcoholic steatohepatitis, fatty liver disease, resmetirom. Study selection, extraction all English-language studies involving use disease (NAFLD)/NASH were included. synthesis: Resmetirom, a thyroid hormone receptor agonist, is administered at daily doses either 80 mg or 100 mg. The drug shown provide NASH resolution as assessed by NAFLD activity score, mg-24.2%, mg-25.9% compared 14.2% with placebo group ( P < 0.001). improved fibrosis, mg-25.9%, mg-29.9% 9.7% Resmetirom’s ability improve fibrosis in patients F2-F3 offers valuable benefit risk progressing cirrhosis. Relevance patient care practice: Resmetirom expands medication options available treat which can given alongside other medications optimize metabolic factors such glucagon-like peptide-1 hydroxymethylglutaryl-coenzyme reductase inhibitors. well tolerated studies. Conclusion: serves an attractive option diagnosed evidence advanced (F2-F3) combination exercise, diet, multimodal therapies targeting factors.

Language: Английский

Does an Aspirin a Day Take the MASLD Away?

Advances in Therapy, Journal Year: 2024, Volume and Issue: 41(7), P. 2559 - 2575

Published: May 15, 2024

Language: Английский